OPKO Health (NASDAQ:OPK) Rating Increased to Hold at Wall Street Zen

OPKO Health (NASDAQ:OPK) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

OPK has been the subject of a number of other research reports. LADENBURG THALM/SH SH upgraded OPKO Health to a “strong-buy” rating in a research note on Tuesday, July 8th. Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Thursday. Zacks Research raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $1.60 target price (down from $2.00) on shares of OPKO Health in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, OPKO Health has a consensus rating of “Hold” and a consensus target price of $2.28.

OPKO Health Price Performance

OPKO Health stock opened at $1.36 on Friday. The firm has a fifty day moving average of $1.46 and a 200-day moving average of $1.38. OPKO Health has a 52-week low of $1.11 and a 52-week high of $2.04. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $1.08 billion, a P/E ratio of -5.44 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.05. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.62%. The business had revenue of $151.67 million for the quarter, compared to analyst estimates of $165.74 million. During the same quarter in the previous year, the business posted $0.03 EPS. The business’s quarterly revenue was down 12.6% on a year-over-year basis. As a group, analysts predict that OPKO Health will post -0.25 EPS for the current year.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the company’s stock in a transaction that occurred on Friday, October 31st. The stock was acquired at an average price of $1.42 per share, for a total transaction of $213,000.00. Following the completion of the purchase, the chief executive officer owned 214,386,448 shares in the company, valued at approximately $304,428,756.16. This represents a 0.07% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 49.69% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in OPKO Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company’s stock valued at $48,970,000 after buying an additional 293,740 shares during the last quarter. AWM Investment Company Inc. lifted its holdings in OPKO Health by 42.3% during the 1st quarter. AWM Investment Company Inc. now owns 1,850,000 shares of the biotechnology company’s stock worth $3,071,000 after buying an additional 550,000 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of OPKO Health by 24.2% in the 1st quarter. GSA Capital Partners LLP now owns 1,343,701 shares of the biotechnology company’s stock worth $2,231,000 after acquiring an additional 261,495 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of OPKO Health by 158.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 74,706 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 45,798 shares during the last quarter. Finally, Washington Growth Strategies LLC increased its holdings in shares of OPKO Health by 67,806,100.0% in the 2nd quarter. Washington Growth Strategies LLC now owns 1,356,124 shares of the biotechnology company’s stock valued at $1,790,000 after acquiring an additional 1,356,122 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.